A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes

NCT00516074 · Completed

Last updated 2026-05-28

This study tests whether the medication exenatide affects the average heart rate over 24 hours in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 54 people

Who can join Ages 18–75 · all sexes

Timeline Started 2007-09 · est. completion 2008-04

Where 6 sites · Canada, Netherlands

What this study is testing ClinicalTrials.gov NCT00516074 ↗

Description as written by the study sponsor.

This study will explore the effect of exenatide (given twice a day) versus placebo (given twice a day) treatment on change in mean 24-hour heart rate over a 12 week period of drug exposure in patients with type 2 diabetes.

Treatments tested

exenatide also known as Byetta, AC2993, LY2148568 Drug

subcutaneous injection, 5mcg or 10mcg, twice a day
placebo Drug

subcutaneous injection, volume equivalent to active, twice a day

Main thing measured	Change in Mean 24-hour Heart Rate From Baseline to Endpoint
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00516074 ↗